Robert Brenner - 04 Feb 2026 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Reporting relationship: Chief Medical Officer
Issuer ticker: VERA
Reported as of: 04 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Feb 2026, 20:00:06 UTC
Prior SEC filing: 20 Feb 2025
Next SEC filing: 25 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph R. Young, Attorney-in-Fact

Key filing fact

Robert Brenner filed Form 4 for Vera Therapeutics, Inc. (VERA) on 06 Feb 2026.

Key facts

This page summarizes Robert Brenner's Form 4 filing for Vera Therapeutics, Inc. (VERA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Feb 2026, 20:00.

Change

Previous filing in this sequence was filed on 20 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002006910 Primary reporting owner

Brenner Robert

Relationship: Chief Medical Officer
Address: C/O VERA THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Signature: /s/ Joseph R. Young, Attorney-in-Fact
Signature date: 06 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VERA transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +25,000
Change %: +89%
Price: $0.000000
Shares after: 53,098
Date: 04 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VERA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 04 Feb 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 50,000
Exercise price: $42.74
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.

Footnote F2

Includes 624 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2025.

Footnote F3

1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.